ALK and lung adenocarcinoma: Furthermore, to validate the results using clinical specimens, we extracted phosphoproteome data for tumour tissue and normal tissue adjacent to the tumour (NAT) in EML4-ALK–positive patients from Clinical Proteomic Tumor Analysis Consortium (CPTAC) lung adenocarcinoma data (Gillette et al, 2020).